Scynexis (SCYX) Net Income towards Common Stockholders (QoQ) (2013 - 2026)
Scynexis (SCYX) Net Income towards Common Stockholders (QoQ) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.92 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Scynexis | 62.02 Mn | -52.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.84% |
| Mar 31, 2026 | -234.03% |
| Dec 31, 2025 | 242.68% |
| Sep 30, 2025 | -24.78% |
| Jun 30, 2025 | -27.71% |
| Mar 31, 2025 | -20.28% |
| Dec 31, 2024 | -59.62% |
| Sep 30, 2024 | 80.58% |
| Jun 30, 2024 | -3,617.76% |
| Mar 31, 2024 | 101.93% |
| Dec 31, 2023 | -1,110.36% |
| Sep 30, 2023 | -101.44% |
| Jun 30, 2023 | 460.90% |
| Mar 31, 2023 | -73.73% |
| Dec 31, 2022 | 34.09% |
| Sep 30, 2022 | -121.69% |
| Jun 30, 2022 | -144.82% |
| Mar 31, 2022 | 81.38% |
| Dec 31, 2021 | -4,739.17% |
| Sep 30, 2021 | -136.49% |